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Abstract
Background and Aims: In patients with advanced liver cirrhosis due to chronic hepatitis C virus (HCV) infection antiviral
therapy with peginterferon and ribavirin is feasible in selected cases only due to potentially life-threatening side effects.
However, predictive factors associated with hepatic decompensation during antiviral therapy are poorly defined.
Methods: In a retrospective cohort study, 68 patients with HCV-associated liver cirrhosis (mean MELD score 9.1862.72) were
treated with peginterferon and ribavirin. Clinical events indicating hepatic decompensation (onset of ascites, hepatic
encephalopathy, upper gastrointestinal bleeding, hospitalization) as well as laboratory data were recorded at baseline and
during a follow up period of 72 weeks after initiation of antiviral therapy. To monitor long term sequelae of end stage liver
disease an extended follow up for HCC development, transplantation and death was applied (240weeks, 6SD 136weeks).
Results: Eighteen patients (26.5%) achieved a sustained virologic response. During the observational period a hepatic
decompensation was observed in 36.8%. Patients with hepatic decompensation had higher MELD scores (10.84 vs. 8.23,
p,0.001) and higher mean bilirubin levels (26.74 vs. 14.63 mmol/l, p,0.001), as well as lower serum albumin levels (38.2 vs.
41.1 g/l, p=0.015), mean platelets (102.64 vs. 138.95/nl, p=0.014) and mean leukocytes (4.02 vs. 5.68/nl, p=0.002) at
baseline as compared to those without decompensation. In the multivariate analysis the MELD score remained
independently associated with hepatic decompensation (OR 1.56, 1.18–2.07; p=0.002). When the patients were grouped
according to their baseline MELD scores, hepatic decompensation occurred in 22%, 59%, and 83% of patients with MELD
scores of 6–9, 10–13, and .14, respectively. Baseline MELD score was significantly associated with the risk for
transplantation/death (p,0.001).
Conclusions: Our data suggest that the baseline MELD score predicts the risk of hepatic decompensation during antiviral
therapy and thus contributes to decision making when antiviral therapy is discussed in HCV patients with advanced liver
cirrhosis.
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Introduction
Chronic hepatitis C virus (HCV) infection is a major health
burden with more than 170 million infected individuals world-
wide. Progression to liver cirrhosis is observed in 2–35% of the
patients after 20–25 years of chronic infection and once liver
cirrhosis is established, the cumulative 5-year risk to develop
hepatocellular carcinoma (HCC) is estimated to be 17% [1,2].
For more than one decade, available antiviral treatment
consisted of a dual therapy with pegylated interferon alfa-2a or -
2b (peginterferon) in combination with the guanosine analog
ribavirin leading to sustained virologic response (SVR) rates in
approximately half of the patients [3,4]. Licensing of the new
HCV protease inhibitors boceprevir and telaprevir, as part of a
triple therapy for untreated HCV genotype 1 patients and those
who failed previous treatment, represents a milestone in HCV
treatment. Untreated patients undergoing triple therapy achieve
significantly higher SVR rates (66–75%) as compared to those
receiving the dual therapy alone (37–44%) [5,6,7]. Patients with a
previous virologic relapse, partial response, or non-response to
peginterferon and ribavirin also benefit when retreated with
boceprevir or telaprevir-containing triple therapies [8,9].
It is well established, that the presence of advanced fibrosis or
compensated liver cirrhosis negatively influence a patient’s
individual chance for achieving an SVR [10]. In turn, patients
with advanced disease may benefit most from antiviral therapy
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studies that SVR can prevent hepatic decompensation, develop-
ment of hepatocellular carcinoma, and is associated with reduced
overall mortality [11,12,13,14]. Albeit still unsatisfactory, sub-
analyses of the pivotal boceprevir and telaprevir trials have shown
that SVR rates for patients with advanced fibrosis and liver
cirrhosis receiving triple therapy are higher as compared to those
receiving peginterferon and ribavirin alone (52–62% vs. 33–38%)
[5,6].
In patients with more severe disease, e.g. patients with advanced
cirrhosis and those on the waiting list for liver transplantation,
successful antiviral therapy in selected cases may halt the
progression of liver disease, can prevent HCV re-infection of the
transplanted liver and subsequently leads to a decrease of post-
transplant morbidity and mortality [15,16,17,18,19,20]. However,
SVR rates in those patients have been shown to be poorer
(approximately 25%) and peginterferon and ribavirin in those
patients is associated with potentially life-threatening side effects
and discontinuation rates ranged from 20–100%.
Recently, preliminary data from the French early access
program for telaprevir and boceprevir (CUPIC study) reporting
antiviral efficacies and the occurrence of adverse events in more
than 400 cirrhotic patients receiving antiviral triple therapy were
presented [21]. About 38–48% of the cirrhotic patients experi-
enced serious adverse events during the first 16 weeks of antiviral
triple therapy and 8 patients died.
Thus, decision making for antiviral therapy in patients with
(advanced) liver cirrhosis remains a clinical challenge facing the
dilemma of increased SVR rates on the one hand and therapeutic
schedules that are associated with increased complications and
fatal outcomes on the other hand [22]. Moreover, predictive
factors in cirrhotic patients that are associated with serious adverse
events and/or hepatic decompensation during antiviral therapy
are poorly defined.
The aim of this retrospective cohort study was to define baseline
characteristics that can help to predict the risk for hepatic
decompensation in HCV patients with advanced liver cirrhosis
during antiviral therapy with peginterferon and ribavirin. Clinical
events indicating hepatic decompensation (ascites, hepatic en-
cephalopathy, upper gastrointestinal bleeding, hospitalization) as
well as laboratory data were recorded at baseline and during a
follow up period of 72 weeks.
Patients and Methods
In this retrospective cohort study we investigated 68 consecutive
patients with advanced liver cirrhosis due to hepatitis C infection
that were treated with pegylated interferon alfa-2a or 2b and
ribavirin between the years 2002 and 2010 at the outpatient liver
clinic of the J. W. Goethe University Hospital in Frankfurt,
Germany. Diagnosis of chronic hepatitis C infection was based on
a positive HCV antibody screening test at least six months before
treatment and detection of HCV RNA in the blood by a
quantitative assay. Liver cirrhosis was diagnosed when typical
clinical features, endoscopical findings, laboratory results, imaging
results or results of liver biopsy or transient elastography were
present.
This cohort of patients with advanced cirrhosis consisted of
individuals who had an episode of hepatic decompensation in the
medical history, were classified beyond Child-Pugh class A at
baseline of therapy, or had laboratory abnormalities (e.g. severe
thrombocytopenia) that would generally exclude the patient from
interferon-based antiviral therapy.
Ethics Statement
The present study was approved by the Ethics Committee of
Goethe University Hospital in Frankfurt, Germany, and written
informed consent was obtained from all patients. The study was
conducted in accordance with the guidelines of the Declaration of
Helsinki and the principles of Good Clinical Practice.
Therapy and Data Gathering
Hepatitis C therapy was administered according to national and
international treatment guidelines [23,24]. Patients were treated
with either pegylated interferon alfa-2a (180 mg subcutaneously
once a week) or -2b (1.0–1.5 mg/kg body weight subcutaneously
once a week) in combination with weight-based dosage of ribavirin
(800 mg–1200 mg daily). Planned treatment durations ranged
from 16 weeks to 48 weeks according to HCV genotype and on-
treatment virologic response. No patient was treated for longer
than 48 weeks. Dose reductions were done according to package
insert recommendations of peginterferon and ribavirin and on a
case-by-case basis at the physicians’ discretion.
Approximately one-third (36.8%) of the patients had an episode
of hepatic decompensation in the medical history or was classified
as having liver cirrhosis beyond Child-Pugh class A by the
initiation of therapy. The remaining patients had laboratory
abnormalities indicating advanced cirrhosis (e.g. pronounced
thrombocytopenia). Thus, the majority of patients were treated
off-label as the label for antiviral therapy with peginterferons and
ribavirin covers patients with well compensated Child-Pugh class
A cirrhosis only. All patients gave informed consent prior to the
initiation of therapy.
Clinical events indicating hepatic decompensation (ascites,
hepatic encephalopathy, upper gastrointestinal bleeding, hospital-
ization) as well as laboratory data were recorded at baseline and
throughout 72 weeks after initiation of antiviral therapy. These
data were collected from electronic and paper files of the patients.
Statistics
Data collection, data management, and statistical analyses were
performed with SPSS software package, release 17.0 (SPSS Inc.,
Chicago, IL). To test for the association of patient parameters with
the risk for hepatic decompensation, Mann–Whitney U tests were
used. For the multivariate analysis backward stepwise logistic
regression was used. The odds ratio and 95% confidence interval
were calculated in order to determine the risk for hepatic
decompensation under therapy. Findings were considered statis-
tically significant at a p value ,0.05 (two-sided).
Results
Baseline characteristics of the 68 patients with advanced liver
cirrhosis due to chronic HCV are summarized in Table 1. Forty-
four (64.7%) of the patients were infected with genotype 1. The
mean model of end stage liver disease (MELD) score at baseline
was 9.19. Fourteen (20.6%) patients had experienced an episode of
hepatic decompensation prior to the start of the antiviral
treatment.
Virologic Response and Discontinuation Rates
SVR was achieved in 18 (26.5%) of the patients (22.7% and
33.8% for genotype 1 and genotype non-1, respectively, p=0.395,
Table 2). The mean treatment duration was 38 weeks. In almost
half of the patients (n=33, 48.5%) treatment was discontinued
early due to non-response (n=23, 33.8%), breakthrough (n=1,
1.5%) or side effects/hepatic decompensation (n=9, 13.2%). In 6
of the 25 cases with hepatic decompensation the therapy was
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stabilized with conservative treatment (e.g. diuretics, treatment for
encephalopathy, antibiotics) so that the antiviral therapy could be
continued. Completion of the planned therapy duration increased
the chance for SVR significantly (full duration: 15 (50%) SVR,
early discontinuation: 3 (7.9%) SVR, p,0.001). The minimum
duration to achieve SVR was 16 weeks in one patient with
genotype 2 infection. Although not statistically significant, a trend
for an association between baseline MELD score and early
therapy discontinuation was observed (p=0.075).
The SVR rates of patients with or without hepatic decompen-
sation did not differ significantly (28.0 vs. 25.6%, p=0.829). The
gamma-glutamyltransferase (GGT) levels at baseline were signif-
icantly lower in patients that achieved an SVR (73 vs. 114 U/l,
p=0.019). No association was documented between baseline
MELD score and SVR (p=0.227) or therapy duration (p=0.104).
Most likely due to the relatively small patient number, no
association between SVR and any other known baseline param-
eter including sex, age and viral load was observed.
On Treatment Hepatic Decompensation
Hepatic decompensation during the 72-weeks period after
initiation of antiviral treatment was observed in 25 cases (36.8%).
In 18 patients (26.5%) development of ascites occurred, four
patients (5.9%) experienced an episode of hepatic encephalopathy
and 19 patients (27.9%) had to be hospitalized. Three of the
hospitalized patients were admitted due to serious complications.
One patient was hospitalized for treatment of severe pneumonia
with sepsis. Two patients were hospitalized for acute portal vein
thrombosis under antiviral treatment. In our patient collective no
gastrointestinal bleeding was reported in the observational period.
No patient died during the treatment or the follow-up period.
Baseline Predictors of Hepatic Decompensation
In the univariate statistic analysis several baseline parameters
differed significantly between patients with hepatic decompensa-
tion and patients without hepatic decompensation during the
observational period (Table 3). Patients with hepatic decompen-
sation had higher baseline MELD scores (11 vs. 8, p,0.001),
mean bilirubin levels (1.56 vs. 0.86 mg/dl, p,0.001), INR (1.27
vs. 1.14, p=0.001) and AST/ALT ratios (1.28 vs. 0.95, p=0.005),
as well as lower mean serum albumin levels (3.82 vs. 4.11 g/dl,
p=0.015), hemoglobin levels (13.28 vs. 14.25 g/dl, p=0.044),
platelets (103 vs. 139/nl, p=0.014) and leukocytes (4.02 vs. 5.68/
nl, p=0.002) at baseline (Table 3). No association was observed
for creatinine (0.87 vs. 0.82 mg/dl, p=0.56), age (52.8 vs. 50.9
years, p=0.80), treatment duration (37.5 vs. 38.1 months,
p=0.755) or gender (p=0.99).
For the multivariate logistic regression analysis only those
parameters were included that were significantly associated with
hepatic decompensation in the univariate comparisons. In the
multivariate analysis only the MELD score was shown to be
independently associated with hepatic decompensation during
antiviral therapy (p=0.002) whereas all other parameters dropped
out. The Odds ratio was calculated 1.56 (1.18–2.07), which shows
that every increase in the MELD score of one point is associated
with a 1.56-fold increased risk for decompensation (Table 3).
To better characterize the individual risk for hepatic decom-
pensation, the patients were grouped according to their baseline
MELD scores. Hepatic decompensation was observed in 22%
(n=10/54) of the patients with a MELD score of 6–9, in 59%
(n=10/17) of the patients with a MELD score between 10 and 13
and 83% (n=5/6) of the patients with a MELD score above 14
(Figure 1).
Extended Follow Up for HCC, Transplantation and Death
72 weeks of follow up after the start of antiviral treatment allow
for the classification of treatment response and treatment related
decompensation. To monitor long term sequelae of end stage liver
disease an extended follow up for HCC development, transplan-
tation and death was applied. Patients were followed for a mean
Table 1. Baseline characteristics of the study cohort.
Patients (n=68)
Age (years) 51.3 (28–69)
Sex (males), n (%) 37 (54.4)
HCV RNA (log10 IU/ml) 6.35 (2.34–7.21)
HCV genotype
1, n (%) 44 (64.7)
2, n (%) 6 (8.8)
3, n (%) 13 (19.1)
4, n (%) 5 (7.4)
ALT (IU/L) 87 (17–349)
AST/ALT ratio 1.07 (0.45–2.67)
Platelet counts (/nl) 125 (33–281)
Leukocytes (/nl) 5.05 (1.47–13.67)
Hemoglobin (g/dl) 13.87 (7.8–17.6)
MELD score 9.19 (5–20)
Total bilirubin (mg/dl) 1.12 (0.3–4.4)
INR 1.19 (0.92–1.54)
Creatinine (mg/dl) 0.84 (0.46–1.93)
Previous decompensation, n (%) 14 (20.6)
Qualitative variables are shown in n (%) and quantitative variables are
expressed as mean (range). AST, aspartate aminotransferase; ALT, alanine
aminotransferase; MELD, Model for End-stage Liver Disease.
doi:10.1371/journal.pone.0071262.t001
Table 2. Treatment and decompensation parameters.
Patients (n=68)
Treatment duration (weeks) 37.9 (4–48)
SVR 18 (26.5)
Genotype 1 10 (22.7)
Genotype non-1 8 (33.3)
Decompensation 25 (36.8)
Ascites 18 (26.5)
Encephalopathy 4 (5.9)
GI-Bleeding 0 (0)
Hospitalization 19 (27.9)
Treatment discontinuation 33 (48.5)
due to Decompensation/side effects 6 (8.8)
Side effects 3 (4.4)
Nonresponse 23 (33.8)
Breakthrough 1 (1.5)
Qualitative variables are shown in n (%) and quantitative variables are
expressed as mean (range). SVR, sustained virologic response.
doi:10.1371/journal.pone.0071262.t002
MELD Score Predicts Decompensation in HCV Therapy
PLOS ONE | www.plosone.org 3 August 2013 | Volume 8 | Issue 8 | e71262period of 240 weeks (6SD 136 weeks) after initiation of antiviral
therapy. HCC, transplantation or death occurred in 14 patients
(20.6%). Five patients died (7.4%), five underwent liver transplan-
tation (7.4%) and eight patients developed hepatocellular carci-
noma (11.8%). None of the patients that achieved SVR needed
liver transplantation or died in comparison to 20.0% of patients
without SVR. Due to the small numbers the difference did not
reach statistical significance (p=0.052).
Baseline MELD score was significantly associated with the risk
for transplantation/death (p,0.001) but not for the development
of HCC (p=0.231). Transplantation or death occurred in 2.2% of
the low MELD patients (,10), in 35.3% of the medium MELD
patients (11–13) and 50% in the high MELD patients (.13).
Discussion
In HCV patients with bridging fibrosis or compensated liver
cirrhosis SVR is clearly associated with an improved long-term
clinical outcome. Hence, international treatment guidelines
generally recommend antiviral therapy in this patient group
[24,25]. In individuals with more advanced disease, i.e. beyond
Child-Pugh class A liver cirrhosis, individual decision making and
treatment in an experienced liver clinic with a liver transplant
program is recommended [26]. Successful antiviral treatment in
patients with advanced cirrhosis may halt progression of liver
disease or prevent HCV re-infection of the liver graft in those
awaiting liver transplantation [22]. There are only few controlled
studies available in patients with advanced or even decompensated
liver cirrhosis. However, these studies provided evidence that SVR
rates of less than 25% are achievable with peginterferon and
Table 3. Association of baseline parameters with hepatic decompensation in univariate and multivariate analyses.
baseline parameter hepatic decompensation Univariate p-value Multivariate OR (95% CI) p-value
yes no
MELD score 11 8 ,0.001 OR 1.56 (1.18–2.07), p=0.002
Bilirubin [mmol/l] 1.56 0.86 ,0.001 n.s.
INR 1.27 1.14 0.001 n.s.
Creatinine [mg/dl] 0.87 0.82 0.563 –
Platelets [/nl] 103 139 0.014 n.s.
Leukocytes [/nl] 4.02 5.68 0.002 n.s.
Albumin [g/l] 38.2 41.1 0.015 n.s.
Hemoglobin [g/dl] 13.28 14.25 0.044 n.s.
Age [years] 51.84 50.93 0.798 –
AST/ALT ratio 1.28 0.95 0.005 n.s.
Baseline parameters are expressed as means. AST, aspartate aminotransferase; ALT, alanine aminotransferase; MELD, Model for End-stage Liver Disease; OR, odds ratio.
doi:10.1371/journal.pone.0071262.t003
Figure 1. Frequency of decompensation according to the baseline MELD score. A low, moderate and high risk for decompensation in three
MELD groups is shown (mean risk in each group was 22%, 59%, and 83%, respectively). The risk for decompensation during antiviral therapy
increases with every increase in the baseline MELD score.
doi:10.1371/journal.pone.0071262.g001
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worsening of liver function and life-threatening side effects [15,16].
In the present study, we retrospectively analyzed all patients
with advanced cirrhosis who underwent antiviral therapy with
peginterferon and ribavirin at our center between 2002 and 2010
(n=68) and we assessed virologic efficacy, frequency of clinical
events reflecting hepatic decompensation, and aimed to detect
predictive parameters for patients at risk for decompensation. The
overall SVR rate in our patient cohort was 26.5% and was
comparable to other studies that assessed treatment outcomes in
advanced cirrhosis patients [15]. The rate of hepatic decompen-
sation defined as onset of ascites, hepatic encephalopathy, upper
gastrointestinal bleeding or hospitalization was 36.8% in our
cohort. The overall discontinuation rate was 48.5% including
those who were discontinued due to hepatic decompensation and/
or other serious adverse events (13.2%) and those who had a
virologic non-response or breakthrough (35.3%). In previous
studies, discontinuation rates ranged from 20–100% [22].
We retrospectively performed a multivariate analysis including a
variety of baseline laboratory values as well as the MELD score to
identify predictive factors associated with subsequent hepatic
decompensation. Our data show that the baseline MELD score is
independently associated with the risk for hepatic decompensation
during antiviral therapy in our patient cohort. More detailed,
every increase in the MELD score of one point increases the risk
for hepatic decompensation 1.56 fold. When the patients were
grouped according to their baseline MELD scores, hepatic
decompensation occurred in 22%, 59%, and 83% of patients
with baseline MELD scores of 6–9, MELD scores 10–13, and
MELD scores .14. The MELD score was initially designed and
established as a parameter to predict the 3-month mortality in
patients who received a transjugular intrahepatic stent shunt and is
currently used for the allocation of organ grafts in liver
transplantation in the United Network for Organ Sharing (UNOS)
and the Eurotransplant network [27]. In recent years, the MELD
score has also been proven to predict perioperative mortality in
patients with advanced liver disease [28,29]. Our data suggest that
the MELD score may also help to select patients with advanced
liver cirrhosis in whom antiviral therapy with peginterferon and
ribavirin is discussed.
The introduction of the HCV protease inhibitors boceprevir
and telaprevir has substantially increased SVR rates in untreated
HCV genotype 1 patients and those who failed previous treatment
as compared to peginterferon and ribavirin alone [30]. Moreover,
so-called difficult-to-treat patient groups including individuals with
advanced fibrosis or liver cirrhosis achieve higher SVR rates with
the triple therapy as compared to those receiving dual therapy.
Thus, the motivation to treat patients with more advanced disease
may rise in the near future. Data from the French early access
program for telaprevir and boceprevir (CUPIC study) showed that
60–80% of the cirrhotic and prior non-responder patients were
tested negative for HCV RNA early during treatment but serious
adverse events occurred in 38–48% of all patients studied thus far
and 8 patients died during the treatment period. This unexpect-
edly high frequency of serious adverse events differs from that seen
in recent registration trials for boceprevir and telaprevir and raises
important questions about safety and feasibility of antiviral
treatment in cirrhotic patients. It is noteworthy, however, that
approximately 30% of patients treated in the CUPIC study would
not have been eligible for one of the boceprevir or telaprevir
registration trials due to clinical or laboratory signs of advanced
liver cirrhosis (beyond Child-Pugh class A) [21].
Our data show that already with a MELD score of 10 or higher
the risk for decompensation under therapy is markedly increased.
Nevertheless, this patient group should not per se be excluded
from antiviral therapy with pegylated interferon and ribavirin.
Under close clinical monitoring, deterioration of liver function and
hepatic decompensation can be observed early and thus potential
risks minimized. Treatment decision and supervision for this
patient group should be in the hands of physicians with experience
in the treatment of end stage liver disease and HCV therapy. Since
the risk for decompensation in patients with a MELD score above
13 is even higher, treatment in this patient group should be
considered in exceptional cases only. Treatment should ideally be
reserved to transplant centers and even the listing for liver
transplantation prior to the initiation of therapy should be
considered.
Fortunately, we did not observe any therapy associated deaths
in our patient cohort treated with dual therapy and hepatic
decompensation could be managed by repeat clinical consultations
and supportive treatment approaches in all patients. Earlier
antiviral treatment studies have shown that infectious complica-
tions predominantly occur in advanced liver cirrhosis and
antibiotic prophylaxis for patients with onset of ascites was
proposed as a supportive treatment [31]. In the controlled trial by
Iacobellis et al., the odds ratios were 2.95 for severe infection and
1.97 for dying from infection in treated decompensated patients
with cirrhosis as compared to non-treated cirrhotic controls.
Infections were associated with decreased liver function as
expressed by the Child Pugh score and also by increasing MELD
scores [15]. In line with this, a recent study by Roomer et al.
showed that the neutrophile count of HCV patients during
therapy cannot predict the risk for bacterial infections and dose
reduction of peginterferon was not associated with a decrease of
the infection rate [32].
The extended follow up period for the end points HCC,
transplantation and death showed an association between MELD
score and death/transplantation, as expected, demonstrating the
integrity of our data. None of the patients with SVR needed liver
transplantation or died during the follow up period which
underlines the need for highly effective treatment regimes.
Currently, interferon-free treatment regimens evolve and may
be available for many patients with chronic hepatitis C in the near
future [33]. The combination of different classes of direct-acting
antiviral agents, with or without ribavirin has been shown to result
in high SVR rates in early clinical studies and showed dramatically
better tolerability profiles as compared to interferon-based
therapies [34,35,36,37,38]. Future studies are needed to show
that interferon-free antiviral treatment is effective and feasible in
HCV patients with advanced or decompensated liver cirrhosis.
In summary, our data showed that the baseline MELD score
can be used to predict the risk for hepatic decompensation during
peginterferon and ribavirin treatment in HCV patients with
cirrhosis. Since there is accumulating evidence that severe
complications in cirrhotic patients may occur more frequently
during triple therapy with boceprevir and telaprevir, more studies
are needed in larger cohorts to refine safety guidelines in these
difficult-to-treat patients.
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